Felix C. Ringshausen

Jul 3, 2024 | err.ersjournals.com | James Chalmers |Felix C. Ringshausen

It is our pleasure to introduce a review series in the European Respiratory Review for the World Bronchiectasis Conference 2024, covering key clinical topics and perspectives for future research in this exciting field. This is a time of great progress and change in the field of bronchiectasis. The past 10 years have seen an acceleration of clinical research with major advances in our understanding of the epidemiology, pathophysiology and heterogeneity of the disease [1].

Apr 18, 2024 | erj.ersjournals.com | Stefano Aliberti |Felix C. Ringshausen |Charles S. Haworth |Michael R Loebinger

IntroductionBronchiectasis is a chronic inflammatory disease [1, 2]. Although it is recognised that bronchiectasis is composed of multiple phenotypes and endotypes, inflammation has classically been regarded as neutrophilic and patients with higher levels of neutrophilic inflammation have been shown to have worse clinical outcomes [3–5]. Although there are composite severity and prognostic assessment tools for bronchiectasis, there are currently no direct measures of inflammation [5–7].

Apr 12, 2024 | erj.ersjournals.com | Stefano Aliberti |Felix C. Ringshausen |Charles S. Haworth |Michael R Loebinger

FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Aug 31, 2023 | thelancet.com | Felix C. Ringshausen |Adam Shapiro |Kim Nielsen

Summary Mucociliary clearance is dysfunctional in people with primary ciliary dyskinesia, resulting in the accumulation of dehydrated mucus in the airways that is difficult to clear. We undertook a study to assess the benefit on lung function of treatment with a nebulised epithelial sodium channel (ENaC) blocker, idrevloride, with or without hypertonic saline, in people with primary ciliary dyskinesia.

Apr 24, 2023 | thelancet.com | James Chalmers |Eva Polverino |Megan L. Crichton |Felix C. Ringshausen

Having observed that patients in central and eastern Europe were more likely to have severe cystic bronchiectasis and were less likely to receive evidence-based treatments, we investigated whether this translated into more exacerbations during follow-up. For this analysis of regional differences in exacerbations, we included 9978 patients who had at least 1 year of follow-up data.